Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Fruman

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
Current Topics in Microbiology and Immunology|June 22, 2010
PI3Ks in lymphocyte signaling and developmentKlaus Okkenhaug, David A Fruman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2010
Target of rapamycin signaling in leukemia and lymphomaCollin Vu, David A Fruman
Autoimmunity|August 31, 2007
Role of phosphoinositide 3-kinase signaling in autoimmunityJean S Oak, David A Fruman
Annals of the New York Academy of Sciences|April 5, 2013
Achieving cancer cell death with PI3K/mTOR-targeted therapiesSung Su Yea, David A Fruman
Science Signaling|August 12, 2010
B cell receptor signaling: picky about PI3KsJose J Limon, David A Fruman
Seminars in Cell & Developmental Biology|June 24, 2004
PI3K signaling controls cell fate at many points in B lymphocyte development and activationAmber C Donahue, David A Fruman
Seminars in Immunology|March 9, 2002
Phosphoinositide 3-kinase in immunological systemsDavid A Fruman, Lewis C Cantley
The Biochemical Journal|May 10, 2008
Cancer therapy: staying current with AMPKDavid A Fruman, Aimee L Edinger
Oncotarget|July 27, 2010
Targeting TOR dependence in cancerMatthew R Janes, David A Fruman
Annual Review of Immunology|March 23, 2004
Phosphoinositide 3-kinase: diverse roles in immune cell activationJonathan A Deane, David A Fruman
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
Current Topics in Microbiology and Immunology|June 22, 2010
PI3Ks in lymphocyte signaling and developmentKlaus Okkenhaug, David A Fruman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2010
Target of rapamycin signaling in leukemia and lymphomaCollin Vu, David A Fruman
Autoimmunity|August 31, 2007
Role of phosphoinositide 3-kinase signaling in autoimmunityJean S Oak, David A Fruman
Annals of the New York Academy of Sciences|April 5, 2013
Achieving cancer cell death with PI3K/mTOR-targeted therapiesSung Su Yea, David A Fruman
Science Signaling|August 12, 2010
B cell receptor signaling: picky about PI3KsJose J Limon, David A Fruman
Seminars in Cell & Developmental Biology|June 24, 2004
PI3K signaling controls cell fate at many points in B lymphocyte development and activationAmber C Donahue, David A Fruman
Seminars in Immunology|March 9, 2002
Phosphoinositide 3-kinase in immunological systemsDavid A Fruman, Lewis C Cantley
The Biochemical Journal|May 10, 2008
Cancer therapy: staying current with AMPKDavid A Fruman, Aimee L Edinger
Oncotarget|July 27, 2010
Targeting TOR dependence in cancerMatthew R Janes, David A Fruman
Annual Review of Immunology|March 23, 2004
Phosphoinositide 3-kinase: diverse roles in immune cell activationJonathan A Deane, David A Fruman
Pageof 11